{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T07:23:47Z","timestamp":1788593027489,"version":"build-2803163510"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003704","name":"Korea Research Institute of Chemical Technology","doi-asserted-by":"publisher","award":["SI2131-10, KK-2131-20, SI2231-10, KK2331-10, and KK2431-10"],"award-info":[{"award-number":["SI2131-10, KK-2131-20, SI2231-10, KK2331-10, and KK2431-10"]}],"id":[{"id":"10.13039\/501100003704","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurochem Res"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s11064-025-04404-z","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T02:40:23Z","timestamp":1745548823000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Neuroprotective Activities of Sertraline, Tiagabine, and Bicifadine with Autophagy-Inducing Potentials in a 6-Hydroxidopamine-Treated Parkinson\u2019s Disease Cell Model"],"prefix":"10.1007","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9221-2910","authenticated-orcid":false,"given":"Chaemi","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4762-8693","authenticated-orcid":false,"given":"Seong Soon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2997-5018","authenticated-orcid":false,"given":"Myung Ae","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3540-0448","authenticated-orcid":false,"given":"Seong Hwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,25]]},"reference":[{"key":"4404_CR1","doi-asserted-by":"publisher","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","volume":"3","author":"W Poewe","year":"2017","unstructured":"Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, Schrag AE, Lang AE (2017) Parkinson disease. Nat Rev Dis Primers 3:17013","journal-title":"Nat Rev Dis Primers"},{"key":"4404_CR2","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.jsps.2021.01.004","volume":"29","author":"K Orayj","year":"2021","unstructured":"Orayj K, Akbari A, Lacey A, Smith M, Pickrell O, Lane EL (2021) Factors affecting the choice of first-line therapy in Parkinson\u2019s disease patients in Wales: A population-based study. Saudi Pharm J 29:206\u2013212","journal-title":"Saudi Pharm J"},{"key":"4404_CR3","doi-asserted-by":"publisher","first-page":"108085","DOI":"10.1016\/j.neuropharm.2020.108085","volume":"171","author":"W Poewe","year":"2020","unstructured":"Poewe W, Seppi K, Marini K, Mahlknecht P (2020) New hopes for disease modification in Parkinson\u2019s disease. Neuropharmacology 171:108085","journal-title":"Neuropharmacology"},{"key":"4404_CR4","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/S1474-4422(09)70062-6","volume":"8","author":"EC Hirsch","year":"2009","unstructured":"Hirsch EC, Hunot S (2009) Neuroinflammation in Parkinson\u2019s disease: a target for neuroprotection? Lancet Neurol 8:382\u2013397","journal-title":"Lancet Neurol"},{"key":"4404_CR5","doi-asserted-by":"crossref","unstructured":"Sarkar S, Raymick J, Imam S (2016) Neuroprotective and Therapeutic Strategies against Parkinson\u2019s Disease: Recent Perspectives. Int J Mol Sci 17","DOI":"10.3390\/ijms17060904"},{"key":"4404_CR6","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2174\/1570159X17666181127125704","volume":"17","author":"I Carrera","year":"2019","unstructured":"Carrera I, Cacabelos R (2019) Current drugs and potential future neuroprotective compounds for Parkinson\u2019s disease. Curr Neuropharmacol 17:295\u2013306","journal-title":"Curr Neuropharmacol"},{"key":"4404_CR7","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1038\/ncb0910-842","volume":"12","author":"F Madeo","year":"2010","unstructured":"Madeo F, Tavernarakis N, Kroemer G (2010) Can autophagy promote longevity? Nat Cell Biol 12:842\u2013846","journal-title":"Nat Cell Biol"},{"key":"4404_CR8","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/nrn3961","volume":"16","author":"FM Menzies","year":"2015","unstructured":"Menzies FM, Fleming A, Rubinsztein DC (2015) Compromised autophagy and neurodegenerative diseases. Nat Rev Neurosci 16:345\u2013357","journal-title":"Nat Rev Neurosci"},{"key":"4404_CR9","doi-asserted-by":"publisher","first-page":"e8753","DOI":"10.1371\/journal.pone.0008753","volume":"5","author":"M Riedel","year":"2010","unstructured":"Riedel M, Goldbaum O, Schwarz L, Schmitt S, Richter-Landsberg C (2010) 17-AAG induces cytoplasmic alpha-synuclein aggregate clearance by induction of autophagy. PLoS ONE 5:e8753","journal-title":"PLoS ONE"},{"key":"4404_CR10","doi-asserted-by":"crossref","unstructured":"Limanaqi F, Biagioni F, Busceti CL, Ryskalin L, Polzella M, Frati A, Fornai F (2019) Phytochemicals bridging autophagy induction and Alpha-Synuclein degradation in parkinsonism. Int J Mol Sci 20","DOI":"10.3390\/ijms20133274"},{"key":"4404_CR11","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1038\/s41467-020-15119-w","volume":"11","author":"I Choi","year":"2020","unstructured":"Choi I, Zhang Y, Seegobin SP, Pruvost M, Wang Q, Purtell K, Zhang B, Yue Z (2020) Microglia clear neuron-released alpha-synuclein via selective autophagy and prevent neurodegeneration. Nat Commun 11:1386","journal-title":"Nat Commun"},{"key":"4404_CR12","doi-asserted-by":"publisher","first-page":"13107","DOI":"10.1074\/jbc.M110.100420","volume":"285","author":"A Caccamo","year":"2010","unstructured":"Caccamo A, Majumder S, Richardson A, Strong R, Oddo S (2010) Molecular interplay between mammalian target of Rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments. J Biol Chem 285:13107\u201313120","journal-title":"J Biol Chem"},{"key":"4404_CR13","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/acel.12057","volume":"12","author":"A Caccamo","year":"2013","unstructured":"Caccamo A, Magri A, Medina DX, Wisely EV, Lopez-Aranda MF, Silva AJ, Oddo S (2013) mTOR regulates Tau phosphorylation and degradation: implications for Alzheimer\u2019s disease and other Tauopathies. Aging Cell 12:370\u2013380","journal-title":"Aging Cell"},{"key":"4404_CR14","doi-asserted-by":"publisher","first-page":"222","DOI":"10.4161\/auto.8.2.18599","volume":"8","author":"MT Viscomi","year":"2012","unstructured":"Viscomi MT, D\u2019Amelio M, Cavallucci V, Latini L, Bisicchia E, Nazio F, Fanelli F, Maccarrone M, Moreno S, Cecconi F, Molinari M (2012) Stimulation of autophagy by Rapamycin protects neurons from remote degeneration after acute focal brain damage. Autophagy 8:222\u2013235","journal-title":"Autophagy"},{"key":"4404_CR15","doi-asserted-by":"publisher","first-page":"5815","DOI":"10.1007\/s12035-016-0129-3","volume":"54","author":"AK Singh","year":"2017","unstructured":"Singh AK, Kashyap MP, Tripathi VK, Singh S, Garg G, Rizvi SI (2017) Neuroprotection through Rapamycin-Induced activation of autophagy and PI3K\/Akt1\/mTOR\/CREB signaling against Amyloid-beta-Induced oxidative stress, synaptic\/neurotransmission dysfunction, and neurodegeneration in adult rats. Mol Neurobiol 54:5815\u20135828","journal-title":"Mol Neurobiol"},{"key":"4404_CR16","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.4103\/1673-5374.371381","volume":"18","author":"T Liu","year":"2023","unstructured":"Liu T, Wang P, Yin H, Wang X, Lv J, Yuan J, Zhu J, Wang Y (2023) Rapamycin reverses ferroptosis by increasing autophagy in MPTP\/MPP(+)-induced models of Parkinson\u2019s disease. Neural Regen Res 18:2514\u20132519","journal-title":"Neural Regen Res"},{"key":"4404_CR17","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1523\/JNEUROSCI.3944-09.2010","volume":"30","author":"C Malagelada","year":"2010","unstructured":"Malagelada C, Jin ZH, Jackson-Lewis V, Przedborski S, Greene LA (2010) Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson\u2019s disease. J Neurosci 30:1166\u20131175","journal-title":"J Neurosci"},{"key":"4404_CR18","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S0301-0082(01)00003-X","volume":"65","author":"D Blum","year":"2001","unstructured":"Blum D, Torch S, Lambeng N, Nissou M, Benabid AL, Sadoul R, Verna JM (2001) Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson\u2019s disease. Prog Neurobiol 65:135\u2013172","journal-title":"Prog Neurobiol"},{"key":"4404_CR19","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/BF03033565","volume":"11","author":"N Simola","year":"2007","unstructured":"Simola N, Morelli M, Carta AR (2007) The 6-hydroxydopamine model of Parkinson\u2019s disease. Neurotox Res 11:151\u2013167","journal-title":"Neurotox Res"},{"key":"4404_CR20","doi-asserted-by":"crossref","unstructured":"Guimaraes RP, Ribeiro DL, Dos Santos KB, Godoy LD, Correa MR, Padovan-Neto FE (2021) The 6-hydroxydopamine Rat Model of Parkinson\u2019s Disease. J Vis Exp","DOI":"10.3791\/62923"},{"key":"4404_CR21","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.neuroscience.2011.10.057","volume":"211","author":"J Bove","year":"2012","unstructured":"Bove J, Perier C (2012) Neurotoxin-based models of Parkinson\u2019s disease. Neuroscience 211:51\u201376","journal-title":"Neuroscience"},{"key":"4404_CR22","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.2174\/1381612826666200224112534","volume":"26","author":"Y Morofuji","year":"2020","unstructured":"Morofuji Y, Nakagawa S (2020) Drug development for central nervous system diseases using in vitro Blood-brain barrier models and drug repositioning. Curr Pharm Des 26:1466\u20131485","journal-title":"Curr Pharm Des"},{"key":"4404_CR23","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1017\/S0924270800036425","volume":"10","author":"AF Leentjens","year":"1998","unstructured":"Leentjens AF, Verhey FR, Vreeling FW, van Praag HM (1998) The role of serotonin in Parkinsons\u2019 disease: an integrated approach for research of motor, cognitive and affective symptoms with functional intervention studies. Acta Neuropsychiatr 10:84\u201386","journal-title":"Acta Neuropsychiatr"},{"key":"4404_CR24","doi-asserted-by":"publisher","first-page":"106580","DOI":"10.1016\/j.microc.2021.106580","volume":"169","author":"SS Kim","year":"2021","unstructured":"Kim SS, Lee H-Y, Song JS, Bae M-A, Ahn S (2021) UPLC-MS\/MS-based profiling of 31 neurochemicals in the mouse brain after treatment with the antidepressant nefazodone. Microchem J 169:106580","journal-title":"Microchem J"},{"key":"4404_CR25","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.4103\/1673-5374.135329","volume":"9","author":"W Chen","year":"2014","unstructured":"Chen W, Sun Y, Liu K, Sun X (2014) Autophagy: a double-edged sword for neuronal survival after cerebral ischemia. Neural Regen Res 9:1210\u20131216","journal-title":"Neural Regen Res"},{"key":"4404_CR26","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1016\/j.jmb.2019.12.035","volume":"432","author":"A Djajadikerta","year":"2020","unstructured":"Djajadikerta A, Keshri S, Pavel M, Prestil R, Ryan L, Rubinsztein DC (2020) Autophagy induction as a therapeutic strategy for neurodegenerative diseases. J Mol Biol 432:2799\u20132821","journal-title":"J Mol Biol"},{"key":"4404_CR27","doi-asserted-by":"publisher","first-page":"381","DOI":"10.14348\/molcells.2015.0034","volume":"38","author":"J Nah","year":"2015","unstructured":"Nah J, Yuan J, Jung YK (2015) Autophagy in neurodegenerative diseases: from mechanism to therapeutic approach. Mol Cells 38:381\u2013389","journal-title":"Mol Cells"},{"key":"4404_CR28","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.neuron.2017.01.022","volume":"93","author":"FM Menzies","year":"2017","unstructured":"Menzies FM, Fleming A, Caricasole A, Bento CF, Andrews SP, Ashkenazi A, Fullgrabe J, Jackson A, Jimenez Sanchez M, Karabiyik C, Licitra F, Lopez Ramirez A, Pavel M, Puri C, Renna M, Ricketts T, Schlotawa L, Vicinanza M, Won H, Zhu Y, Skidmore J, Rubinsztein DC (2017) Autophagy and neurodegeneration: pathogenic mechanisms and therapeutic opportunities. Neuron 93:1015\u20131034","journal-title":"Neuron"},{"key":"4404_CR29","doi-asserted-by":"crossref","unstructured":"Papp D, Kovacs T, Billes V, Varga M, Tarnoci A, Hackler L Jr., Puskas LG, Liliom H, Tarnok K, Schlett K, Borsy A, Padar Z, Kovacs AL, Hegedus K, Juhasz G, Komlos M, Erdos A, Gulyas B, Vellai T (2016) AUTEN-67, an autophagy-enhancing drug candidate with potent antiaging and neuroprotective effects. Autophagy 12:273\u2013286","DOI":"10.1080\/15548627.2015.1082023"},{"key":"4404_CR30","doi-asserted-by":"publisher","first-page":"42014","DOI":"10.1038\/srep42014","volume":"7","author":"T Kovacs","year":"2017","unstructured":"Kovacs T, Billes V, Komlos M, Hotzi B, Manzeger A, Tarnoci A, Papp D, Szikszai F, Szinyakovics J, Racz A, Noszal B, Veszelka S, Walter FR, Deli MA, Hackler L Jr., Alfoldi R, Huzian O, Puskas LG, Liliom H, Tarnok K, Schlett K, Borsy A, Welker E, Kovacs AL, Padar Z, Erdos A, Legradi A, Bjelik A, Gulya K, Gulyas B, Vellai T (2017) The small molecule AUTEN-99 (autophagy enhancer-99) prevents the progression of neurodegenerative symptoms. Sci Rep 7:42014","journal-title":"Sci Rep"},{"key":"4404_CR31","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s10072-008-1021-3","volume":"29","author":"S Marino","year":"2008","unstructured":"Marino S, Sessa E, Di Lorenzo G, Digangi G, Alagna A, Bramanti P, Di Bella P (2008) Sertraline in the treatment of depressive disorders in patients with Parkinson\u2019s disease. Neurol Sci 29:391\u2013395","journal-title":"Neurol Sci"},{"key":"4404_CR32","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1002\/mdc3.12507","volume":"4","author":"SE Starkstein","year":"2017","unstructured":"Starkstein SE, Brockman S (2017) Management of depression in Parkinson\u2019s disease: A systematic review. Mov Disord Clin Pract 4:470\u2013477","journal-title":"Mov Disord Clin Pract"},{"key":"4404_CR33","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1080\/15548627.2020.1841953","volume":"17","author":"HY Hwang","year":"2021","unstructured":"Hwang HY, Shim JS, Kim D, Kwon HJ (2021) Antidepressant drug Sertraline modulates AMPK-MTOR signaling-mediated autophagy via targeting mitochondrial VDAC1 protein. Autophagy 17:2783\u20132799","journal-title":"Autophagy"},{"key":"4404_CR34","doi-asserted-by":"publisher","first-page":"10494","DOI":"10.1523\/JNEUROSCI.19-23-10494.1999","volume":"19","author":"S Benmansour","year":"1999","unstructured":"Benmansour S, Cecchi M, Morilak DA, Gerhardt GA, Javors MA, Gould GG, Frazer A (1999) Effects of chronic antidepressant treatments on serotonin transporter function, density, and mRNA level. J Neurosci 19:10494\u201310501","journal-title":"J Neurosci"},{"key":"4404_CR35","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.neulet.2013.06.033","volume":"550","author":"M Taler","year":"2013","unstructured":"Taler M, Miron O, Gil-Ad I, Weizman A (2013) Neuroprotective and procognitive effects of Sertraline: in vitro and in vivo studies. Neurosci Lett 550:93\u201397","journal-title":"Neurosci Lett"},{"key":"4404_CR36","doi-asserted-by":"publisher","first-page":"15720","DOI":"10.1038\/srep15720","volume":"5","author":"J Liu","year":"2015","unstructured":"Liu J, Huang D, Xu J, Tong J, Wang Z, Huang L, Yang Y, Bai X, Wang P, Suo H, Ma Y, Yu M, Fei J, Huang F (2015) Tiagabine protects dopaminergic neurons against neurotoxins by inhibiting microglial activation. Sci Rep 5:15720","journal-title":"Sci Rep"},{"key":"4404_CR37","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13578-023-01049-9","volume":"13","author":"XY Liu","year":"2023","unstructured":"Liu XY, Wang K, Deng XH, Wei YH, Guo R, Liu SF, Zhu YF, Zhong JJ, Zheng JY, Wang MD, Ye QH, He JQ, Guo KH, Zhu JR, Huang SQ, Chen ZX, Lv CS, Wen L (2023) Amelioration of olfactory dysfunction in a mouse model of Parkinson\u2019s disease via enhancing GABAergic signaling. Cell Biosci 13:101","journal-title":"Cell Biosci"},{"key":"4404_CR38","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s12264-017-0170-x","volume":"33","author":"ME Fullard","year":"2017","unstructured":"Fullard ME, Morley JF, Duda JE (2017) Olfactory dysfunction as an early biomarker in Parkinson\u2019s disease. Neurosci Bull 33:515\u2013525","journal-title":"Neurosci Bull"},{"key":"4404_CR39","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1002\/mds.20124","volume":"19","author":"W Bara-Jimenez","year":"2004","unstructured":"Bara-Jimenez W, Dimitrova T, Sherzai A, Favit A, Mouradian MM, Chase TN (2004) Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson\u2019s disease. Mov Disord 19:1183\u20131186","journal-title":"Mov Disord"},{"key":"4404_CR40","doi-asserted-by":"publisher","first-page":"34655","DOI":"10.1038\/srep34655","volume":"6","author":"YS Cho","year":"2016","unstructured":"Cho YS, Yen CN, Shim JS, Kang DH, Kang SW, Liu JO, Kwon HJ (2016) Antidepressant indatraline induces autophagy and inhibits restenosis via suppression of mTOR\/S6 kinase signaling pathway. Sci Rep 6:34655","journal-title":"Sci Rep"},{"key":"4404_CR41","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1089\/rej.2018.2070","volume":"22","author":"AK Singh","year":"2019","unstructured":"Singh AK, Singh S, Tripathi VK, Bissoyi A, Garg G, Rizvi SI (2019) Rapamycin confers neuroprotection against Aging-Induced oxidative stress, mitochondrial dysfunction, and neurodegeneration in old rats through activation of autophagy. Rejuvenation Res 22:60\u201370","journal-title":"Rejuvenation Res"},{"key":"4404_CR42","doi-asserted-by":"crossref","unstructured":"Thellung S, Corsaro A, Nizzari M, Barbieri F, Florio T (2019) Autophagy activator drugs: A new opportunity in neuroprotection from misfolded protein toxicity. Int J Mol Sci 20","DOI":"10.3390\/ijms20040901"},{"key":"4404_CR43","doi-asserted-by":"crossref","unstructured":"Zhu Z, Yang C, Iyaswamy A, Krishnamoorthi S, Sreenivasmurthy SG, Liu J, Wang Z, Tong BC, Song J, Lu J, Cheung KH, Li M (2019) Balancing mTOR Signaling and Autophagy in the Treatment of Parkinson\u2019s Disease. Int J Mol Sci 20","DOI":"10.3390\/ijms20030728"},{"key":"4404_CR44","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nrn3068","volume":"12","author":"J Bove","year":"2011","unstructured":"Bove J, Martinez-Vicente M, Vila M (2011) Fighting neurodegeneration with Rapamycin: mechanistic insights. Nat Rev Neurosci 12:437\u2013452","journal-title":"Nat Rev Neurosci"},{"key":"4404_CR45","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.7150\/ijbs.12930","volume":"11","author":"X Yang","year":"2015","unstructured":"Yang X, Hei C, Liu P, Song Y, Thomas T, Tshimanga S, Wang F, Niu J, Sun T, Li PA (2015) Inhibition of mTOR pathway by Rapamycin reduces brain damage in rats subjected to transient forebrain ischemia. Int J Biol Sci 11:1424\u20131435","journal-title":"Int J Biol Sci"},{"key":"4404_CR46","first-page":"4763","volume":"15","author":"F Wang","year":"2018","unstructured":"Wang F, Chen F, Wang G, Wei S, Fang F, Kang D, Lin Y (2018) Rapamycin provides anti-epileptogenic effect in a rat model of post-traumatic epilepsy via deactivation of mTOR signaling pathway. Exp Ther Med 15:4763\u20134770","journal-title":"Exp Ther Med"},{"key":"4404_CR47","doi-asserted-by":"publisher","first-page":"e0168812","DOI":"10.1371\/journal.pone.0168812","volume":"11","author":"M Zhang","year":"2016","unstructured":"Zhang M, Schmitt-Ulms G, Sato C, Xi Z, Zhang Y, Zhou Y, St George-Hyslop P, Rogaeva E (2016) Drug repositioning for Alzheimer\u2019s disease based on systematic \u2018omics\u2019 data mining. PLoS ONE 11:e0168812","journal-title":"PLoS ONE"},{"key":"4404_CR48","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1016\/j.drudis.2022.02.018","volume":"27","author":"JC Alarcon-Barrera","year":"2022","unstructured":"Alarcon-Barrera JC, Kostidis S, Ondo-Mendez A, Giera M (2022) Recent advances in metabolomics analysis for early drug development. Drug Discov Today 27:1763\u20131773","journal-title":"Drug Discov Today"},{"key":"4404_CR49","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jmsacl.2024.01.002","volume":"31","author":"M Oztug","year":"2024","unstructured":"Oztug M, Vatansever B, Altin G, Akgoz M, Can SZ (2024) An LC-MS\/MS-based platform for the quantification of multiple amyloid beta peptides in surrogate cerebrospinal fluid. J Mass Spectrom Adv Clin Lab 31:40\u201348","journal-title":"J Mass Spectrom Adv Clin Lab"},{"key":"4404_CR50","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s10571-013-9921-z","volume":"33","author":"AR Im","year":"2013","unstructured":"Im AR, Kim YH, Uddin MR, Chae S, Lee HW, Kim YH, Kim YS, Lee MY (2013) Betaine protects against rotenone-induced neurotoxicity in PC12 cells. Cell Mol Neurobiol 33:625\u2013635","journal-title":"Cell Mol Neurobiol"},{"key":"4404_CR51","first-page":"950","volume":"18","author":"M Alirezaei","year":"2015","unstructured":"Alirezaei M (2015) Betaine protects cerebellum from oxidative stress following Levodopa and Benserazide administration in rats. Iran J Basic Med Sci 18:950\u2013957","journal-title":"Iran J Basic Med Sci"},{"key":"4404_CR52","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s12576-015-0360-0","volume":"65","author":"M Alirezaei","year":"2015","unstructured":"Alirezaei M, Khoshdel Z, Dezfoulian O, Rashidipour M, Taghadosi V (2015) Beneficial antioxidant properties of betaine against oxidative stress mediated by Levodopa\/benserazide in the brain of rats. J Physiol Sci 65:243\u2013252","journal-title":"J Physiol Sci"},{"key":"4404_CR53","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.pneurobio.2013.04.004","volume":"106\u2013107","author":"SR Subramaniam","year":"2013","unstructured":"Subramaniam SR, Chesselet MF (2013) Mitochondrial dysfunction and oxidative stress in Parkinson\u2019s disease. Prog Neurobiol 106\u2013107:17\u201332","journal-title":"Prog Neurobiol"},{"key":"4404_CR54","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1111\/j.1742-7843.2007.00153.x","volume":"102","author":"TM Kaariainen","year":"2008","unstructured":"Kaariainen TM, Garcia-Horsman JA, Piltonen M, Huotari M, Mannisto PT (2008) Serotonergic activation after 2-week intrastriatal infusion of L-dopa and slow recovery of circling in rats with unilateral nigral lesions. Basic Clin Pharmacol Toxicol 102:300\u2013307","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"4404_CR55","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1100\/2011\/172893","volume":"11","author":"M Politis","year":"2011","unstructured":"Politis M, Loane C (2011) Serotonergic dysfunction in Parkinson\u2019s disease and its relevance to disability. ScientificWorldJournal 11:1726\u20131734","journal-title":"ScientificWorldJournal"},{"key":"4404_CR56","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1159\/000520302","volume":"21","author":"M Kaiserova","year":"2021","unstructured":"Kaiserova M, Chudackova M, Prikrylova Vranova H, Mensikova K, Kastelikova A, Stejskal D, Kanovsky P (2021) Cerebrospinal fluid levels of 5-Hydroxyindoleacetic acid in Parkinson\u2019s disease and atypical parkinsonian syndromes. Neurodegener Dis 21:30\u201335","journal-title":"Neurodegener Dis"},{"key":"4404_CR57","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/S1734-1140(11)70697-1","volume":"63","author":"R Rejdak","year":"2011","unstructured":"Rejdak R, Junemann A, Grieb P, Thaler S, Schuettauf F, Choragiewicz T, Zarnowski T, Turski WA, Zrenner E (2011) Kynurenic acid and kynurenine aminotransferases in retinal aging and neurodegeneration. Pharmacol Rep 63:1324\u20131334","journal-title":"Pharmacol Rep"},{"key":"4404_CR58","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.ntt.2010.10.002","volume":"33","author":"D Silva-Adaya","year":"2011","unstructured":"Silva-Adaya D, Perez-De La Cruz V, Villeda-Hernandez J, Carrillo-Mora P, Gonzalez-Herrera IG, Garcia E, Colin-Barenque L, Pedraza-Chaverri J, Santamaria A (2011) Protective effect of L-kynurenine and probenecid on 6-hydroxydopamine-induced striatal toxicity in rats: implications of modulating kynurenate as a protective strategy. Neurotoxicol Teratol 33:303\u2013312","journal-title":"Neurotoxicol Teratol"},{"key":"4404_CR59","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.pneurobio.2015.12.009","volume":"155","author":"CK Lim","year":"2017","unstructured":"Lim CK, Fernandez-Gomez FJ, Braidy N, Estrada C, Costa C, Costa S, Bessede A, Fernandez-Villalba E, Zinger A, Herrero MT, Guillemin GJ (2017) Involvement of the kynurenine pathway in the pathogenesis of Parkinson\u2019s disease. Prog Neurobiol 155:76\u201395","journal-title":"Prog Neurobiol"},{"key":"4404_CR60","doi-asserted-by":"publisher","first-page":"2225800","DOI":"10.1080\/14756366.2023.2225800","volume":"38","author":"P Chen","year":"2023","unstructured":"Chen P, Geng X (2023) Research progress on the kynurenine pathway in the prevention and treatment of Parkinson\u2019s disease. J Enzyme Inhib Med Chem 38:2225800","journal-title":"J Enzyme Inhib Med Chem"}],"container-title":["Neurochemical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-025-04404-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11064-025-04404-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-025-04404-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T13:02:49Z","timestamp":1750683769000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11064-025-04404-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,25]]},"references-count":60,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["4404"],"URL":"https:\/\/doi.org\/10.1007\/s11064-025-04404-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5357365\/v1","asserted-by":"object"}]},"ISSN":["0364-3190","1573-6903"],"issn-type":[{"value":"0364-3190","type":"print"},{"value":"1573-6903","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,25]]},"assertion":[{"value":"30 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original publication is updated due to missing funding information.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"154"}}